User:Mr. Ibrahem/Blinatumomab

Blinatumomab, sold under the brand name Blincyto, is a medication used to treat B-cell precursor acute lymphoblastic leukemia. Specifically it is used for CD19-positive cases that have either failed other treatments or are in remission. It is given by injection into a vein.

Common side effects include infection, fever, headache, infusion reactions, low red blood cells, low platelets, and low white blood cells. Other side effects may include pancreatitis. Use in pregnancy may harm the baby. It is a monoclonal antibodies that binds to CD19 found on B cells and CD3 found on T cells, such that the later can kill the former.

Blinatumomab was approved for medical use in the United States in 2014 and Europe in 2015. In the United Kingdom a vial of 38.5 micrograms costs the NHS about £2,020 as of 2021. In the United States this amount costs about 4,500 USD.